Nevro Reports First-Quarter 2024 Financial Results
Retrieved on:
星期二, 五月 7, 2024
FDA, Internet access, SCS, International, Investment, Risk, Depreciation, Research, Webcast, HFX, Journal, Tax, Senior, PDN, Patient, Acquisition, Physician, Event, Christoforou, Hertz, RCT, Chronic pain, GAAP, Growth
REDWOOD CITY, Calif., May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The company also announced additional restructuring steps to advance its strategy and accelerate profitability, raised its adjusted EBITDA guidance and reaffirmed its revenue guidance for the full-year 2024, and announced that Christofer Christoforou has been promoted to the newly created Chief Operating Officer (COO) role.
Key Points:
- REDWOOD CITY, Calif., May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results.
- Reported a first quarter 2024 net loss from operations of $35.8 million; first quarter 2024 adjusted EBITDA was a loss of $9.6 million.
- As previously announced, Nevro will host a conference call today to discuss its financial results.
- The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.